MedTrace Logo

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-02-17

Study results available
· View outcomes & findings →

Summary

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.

Conditions

Interventions

DRUG

CB-839

CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

DRUG

Talazoparib

Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Sam Whiting, MD, PhD · Calithera Biosciences, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2020-07-29
Completion
2020-07-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875313 on ClinicalTrials.gov